Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ESMO 2021
MedTech
ESMO: Owkin's deep learning AI predicts breast cancer relapse
To speed up the race to a 100% survival rate, Owkin's AI model can classify the five-year relapse risk of a patient with early-stage breast cancer.
Andrea Park
Sep 22, 2021 10:25am
Syros targets KRAS-mutant cancer with CDK7 inhibitor
Sep 20, 2021 11:30am
ESMO: Mirati pulls away from Amgen in colorectal cancer
Sep 19, 2021 9:47am
ESMO: Daiichi unveils first early peek at next-gen ADC
Sep 17, 2021 7:30am
Novartis links cancer drug to improved pain, quality of life
Sep 16, 2021 6:05pm
ESMO: Zymeworks lays down marker in fight to unseat Herceptin
Sep 16, 2021 8:50am
